The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis.

2025-01-13
Frontiers in endocrinology 15
- Peiye Zhu
- Yunrui Jin
- Jiya Sun
- Xia Zhou

PubMed: 39872318
DOI: 10.3389/fendo.2024.1463027

Study Design

Type: Meta-Analysis
Sample size: n = 533
Population: patients with type 2 diabetes mellitus (T2DM)
Methods: Meta-analysis of randomized controlled trials; studies up to November 6, 2024; quality assessed using Cochrane Handbook; GRADE system

Background

The effects of resveratrol supplementation on inflammation and oxidative stress in patients with type 2 diabetes mellitus (T2DM) were controversial. A meta-analysis was performed to assess the changes in levels of inflammation and oxidative stress in patients with T2DM.

Methods

Relevant literatures before November 6, 2024 were screened through Web of Science,Embase,the Cochrane Library and other sources (ClinicalTrials, ProQuest Dissertations and Theses). The quality of the literature was evaluated according to the Cochrane Handbook of Systematic Reviews. The study quality was assessed using the risk-of-bias 2 tool and the Grading of Recommendations Assessment,Development and Evaluation (GRADE) system. Review Manager 5.3 conducted meta-analysis of the data included in the literature.

Results

This meta-analysis was conducted in six randomized controlled trials involving 533 participants. Our results showed that supplementation with resveratrol significantly reduced C-reactive protein levels(SMD = -1.40, 95%CI(-2.60, -0.21), P = 0.02; Level of evidence: low), lipid peroxide levels (SMD = -0.99, 95%CI(-1.36, -0.61), P < 0.00001; Level of evidence: low), 8-isoprostanes(SMD = -0.79, 95%CI(-1.16, -0.42), P < 0.0001; Level of evidence: low) and oxidative stress score (SMD = -1.62, 95%CI(-2.49, -0.75), P = 0.0003; Level of evidence: very low). In addition, compared to placebo, Supplementation with resveratrol significantly increased glutathione peroxidase levels (SMD = 0.38, 95%CI(0.03, 0.74), P = 0.04; Level of evidence:low) and catalase levels (SMD = 0.33, 95%CI(0.03, 0.63), P = 0.03; Level of evidence: low). However, no significant difference was observed in improving interleukin-6 levels (SMD = -1.35, 95%CI(-2.75, -0.05), P = 0.06; Level of evidence: very low), tumor necrosis factor α levels (SMD = -3.30, 95%CI(-7.47, 0.87), P = 0.12; Level of evidence: very low), superoxide dismutase levels (SMD = 0.39, 95%CI(-0.26, 1.04), P = 0.24; Level of evidence: very low), total antioxidant capacity levels (SMD = 0.39, 95%CI(-0.23, 1.00), P = 0.21; Level of evidence: very low) and malondialdehyde levels (SMD = -3.36, 95%CI(-10.30, 3.09), P = 0.29; Level of evidence: very low).

Conclusion

Resveratrol improved inflammation and oxidative stress in T2DM patients to some extent. This provides a new idea and method for clinical treatment. However, due to the limitations of the study, more large-sample, multi-center clinical studies are needed to verify this conclusion.

Research Insights

Resveratrol→Increased Antioxidant Enzyme Levels
Supplementation with resveratrol significantly increased glutathione peroxidase levels (SMD = 0.38, 95%CI(0.03, 0.74), P = 0.04; Level of evidence:low)
Effect
Beneficial
Effect size
Moderate
Dose
not specified in abstract
Resveratrol→Increased Catalase Level
Supplementation with resveratrol significantly increased ... catalase levels (SMD = 0.33, 95%CI(0.03, 0.63), P = 0.03; Level of evidence: low)
Effect
Beneficial
Effect size
Moderate
Dose
not specified in abstract
Resveratrol→Increased Superoxide Dismutase Levels
no significant difference was observed in improving ... superoxide dismutase levels (SMD = 0.39, 95%CI(-0.26, 1.04), P = 0.24; Level of evidence: very low)
Effect
Neutral
Effect size
Small
Dose
not specified in abstract
Resveratrol→Increased Total Antioxidant Capacity Level
no significant difference was observed in improving ... total antioxidant capacity levels (SMD = 0.39, 95%CI(-0.23, 1.00), P = 0.21; Level of evidence: very low)
Effect
Neutral
Effect size
Small
Dose
not specified in abstract
Resveratrol→Reduced 8-Isoprostane Level
supplementation with resveratrol significantly reduced ... 8-isoprostanes(SMD = -0.79, 95%CI(-1.16, -0.42), P < 0.0001; Level of evidence: low)
Effect
Beneficial
Effect size
Moderate
Dose
not specified in abstract
Resveratrol→Reduced C-Reactive Protein Levels
supplementation with resveratrol significantly reduced C-reactive protein levels(SMD = -1.40, 95%CI(-2.60, -0.21), P = 0.02; Level of evidence: low)
Effect
Beneficial
Effect size
Large
Dose
not specified in abstract
Resveratrol→Reduced Interleukin-6 Levels
no significant difference was observed in improving interleukin-6 levels (SMD = -1.35, 95%CI(-2.75, -0.05), P = 0.06; Level of evidence: very low)
Effect
Neutral
Effect size
Small
Dose
not specified in abstract
Resveratrol→Reduced Lipid Peroxide Level
supplementation with resveratrol significantly reduced ... lipid peroxide levels (SMD = -0.99, 95%CI(-1.36, -0.61), P < 0.00001; Level of evidence: low)
Effect
Beneficial
Effect size
Large
Dose
not specified in abstract
Resveratrol→Reduced Malondialdehyde Level
no significant difference was observed in improving ... malondialdehyde levels (SMD = -3.36, 95%CI(-10.30, 3.09), P = 0.29; Level of evidence: very low)
Effect
Neutral
Effect size
Small
Dose
not specified in abstract
Resveratrol→Reduced Oxidative Stress Score
supplementation with resveratrol significantly reduced ... oxidative stress score (SMD = -1.62, 95%CI(-2.49, -0.75), P = 0.0003; Level of evidence: very low)
Effect
Beneficial
Effect size
Large
Dose
not specified in abstract
Resveratrol→Reduced Tumor Necrosis Factor Alpha
no significant difference was observed in improving ... tumor necrosis factor α levels (SMD = -3.30, 95%CI(-7.47, 0.87), P = 0.12; Level of evidence: very low)
Effect
Neutral
Effect size
Small
Dose
not specified in abstract